Terguride    (DrugBank: Terguride)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
51全身性強皮症8
86肺動脈性肺高血圧症4

51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
8 / 466 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002586-39-BE
(EUCTR)
19/01/201714/07/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
medac GmbHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3Switzerland;Italy;United Kingdom;Portugal;France;United States;Hungary;Poland;Belgium;Romania;Netherlands;Germany
2EUCTR2015-002586-39-GB
(EUCTR)
18/10/201619/07/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
medac GmbHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3Portugal;France;United States;Hungary;Poland;Belgium;Romania;Netherlands;Germany;Italy;Switzerland;United Kingdom
3EUCTR2015-002586-39-PT
(EUCTR)
03/10/201606/07/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
medac GmbHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3France;United States;Portugal;Hungary;Poland;Belgium;Romania;Netherlands;Germany;Italy;United Kingdom;Switzerland
4EUCTR2015-002586-39-HU
(EUCTR)
20/09/201612/07/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapy in Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
medac GmbHNULLNot Recruiting Female: yes
Male: yes
148Phase 3Portugal;France;United States;Hungary;Poland;Belgium;Romania;Netherlands;Germany;Italy;United Kingdom;Switzerland
5EUCTR2015-002586-39-FR
(EUCTR)
13/09/201621/07/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000171021;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
medac GmbHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3Portugal;United States;France;Hungary;Poland;Belgium;Romania;Netherlands;Germany;Italy;United Kingdom;Switzerland
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-002586-39-DE
(EUCTR)
03/08/201629/06/2016Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - TERGISS Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 19.0;Level: PT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
medac GmbHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3Portugal;France;United States;Hungary;Poland;Belgium;Romania;Netherlands;Germany;Italy;United Kingdom;Switzerland
7EUCTR2015-002586-39-IT
(EUCTR)
27/07/201606/02/2018Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic SclerosisRandomized, Multicenter, Double-Blind, Placebo-Controlled Trial toEvaluate the Efficacy and Safety of Terguride Plus Symptomatic Therapyin Subjects With Diffuse Cutaneous Systemic Sclerosis - Terguride Plus Symptomatic Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis Diffuse cutaneous systemic sclerosis (dcSSc)
MedDRA version: 20.0;Level: LLT;Classification code 10042953;Term: Systemic sclerosis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Terguride
Product Code: /
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Product Name: Terguride
Product Code: /
INN or Proposed INN: TERGURIDE HYDROGENMALEATE
Trade Name: METOCLOPRAMIDE ACCORD - 10 MG COMPRESSE 28 COMPRESSE IN BLISTER PVC/PVDC/AL
Product Name: Metoclopramide
Product Code: /
INN or Proposed INN: METOCLOPRAMIDE
Other descriptive name: METOCLOPRAMIDE
MEDAC GMBHNULLNot RecruitingFemale: yes
Male: yes
148Phase 3Portugal;France;United States;Hungary;Poland;Belgium;Romania;Netherlands;Germany;United Kingdom;Switzerland;Italy
8EUCTR2009-017869-27-DE
(EUCTR)
23/09/201014/07/2010A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis.A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis. Diffuse scleroderma
MedDRA version: 12.1;Level: LLT;Classification code 10012941;Term: Diffuse scleroderma
Product Name: Terguride
Product Code: PR1
INN or Proposed INN: Terguride
Other descriptive name: transdihydrolisuride
University Hospital ZurichNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
14Germany

86. 肺動脈性肺高血圧症 [臨床試験数:1,083,薬物数:667(DrugBank:122),標的遺伝子数:98,標的パスウェイ数:185
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 1,083 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-003975-38-AT
(EUCTR)
03/10/201028/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
99Phase 2Czech Republic;Germany;Netherlands;Austria
2EUCTR2007-003975-38-CZ
(EUCTR)
19/05/200913/02/2009Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Germany;Czech Republic;Netherlands;Austria
3EUCTR2007-003975-38-NL
(EUCTR)
18/02/200817/10/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0,5mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Czech Republic;Germany;Netherlands;Austria
4EUCTR2007-003975-38-DE
(EUCTR)
22/11/200728/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0,5mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
99Phase 2Czech Republic;Austria;Netherlands;Germany